INTRODUCTION
Histamine mediates the early stages of vasodilation and increased vascular permeability which characterize the acute inflammatory response (1) . Since histamine is normally sequestered in the storage granules of tissue mast cells and circulating basophils, the control of histamine release may be central to the regulation of the inflammatory response. We recently described a possible endogenous mechanism for histamine release. In this system, factors in human leukocyte and platelet lysates release histamine from intact human leukocytes in vitro (2) . Optimal histamine release occurs under physiological conditions, and intact, metabolically active cells are required (3, 4) . The release reaction is specific, noncytotoxic, and complement independent, and it resembles a secretory process (3, 4) . In addition, histamine release is modulated by cyclic AMP in a unique reversible system where agents which increase cyclic AMP stimulate reabsorption of previously released histamine (5). Our studies have also shown that leukocyte lysates release histamine in vivo using a canine model (6) .
The chemical nature of the leukocyte histamine-releasing factors has remained obscure. Whereas the human platelet factors appear to be cationic protein, the leukocyte factors are not (2) . Part of the difficulty in identifying these factors has been their marked lability: lysates rapidly lose their histamine-releasing activity even at room temperature. In the present studies we describe some preliminary characteristics of the heatlabile human leukocyte histamine-releasing factor. In addition, we describe an inhibitor of histamine release which is generated during thermal inactivation of the histamine-releasing activity at 380C.
METHODS
Preparation of leukocytes and leukocyte lysates. The leukocytes used .in these studies were prepared from the blood of normal human donors by dextran sedimentation as previously described (2) . Purified lymphocyte suspensions were prepared by a modification of the glass-bead column technique of Rabinowitz, described elsewhere (2) .
Purified granulocyte suspensions were prepared by sedimentation through a Ficoll-Hypaque cushion followed by dextran sedimentation as detailed by B6yum (7) . Con (8) . Lysates of these suspensions were prepared by ultrasonic disruption, as previously described (2) . For histamine release assays, mixed leukocyte suspensions were washed in Tris A and resuspended at a concentration of 1 X 107/ml in Tris ACM (Tris A supplemented with Ca++ and Mg++) (8) .
Histamine release assay. The histamine-releasing activity of leukocyte lysates was determined by a previously described modification of the procedure of Lichtenstein and Osler (2, 8) . Histamine was determined fluorometrically, as previously described (8) .
Histamine release inhibition assay. 10 million leukocytes (final concentration 2.5 X 106/tl) were incubated for 60 min at 38°C in 4.0 ml Tris ACM containing the heated lysate inhibitor (0.1-1.0 jsg lysate protein/ml). The cells were then collected by centrifugation and resuspended in 3.5 ml Tris ACM. 0.5 ml of a histamine-releasing agent was added to the resulting leukocyte suspensions. After 60 min incubation at 38°C, the histamine released into the incubation mixture supernate was determined. Total leukocyte histamine was assayed after perchloric acid lysis (8) , and the percent histamine release was determined based on these values for each experiment. In most experiments, the histamine-releasing agent was fresh leukocyte lysate which had been maintained in the cold to preserve histamine-releasing activity. The final concentration of fresh leukocyte lysate was adjusted to 0.25-1.0 gg protein/ml which provided optimal histamine release. In some experiments, compound 48/80 (9), goat antihuman IgE (10) TEMPERATURE (0C) FIGURE 2 Generation of an inhibitor of histamine release during thermal inactivation of leukocyte lysates. Leukocyte lysates, incubated for 30 min at the temperatures indicated, were assayed for leukocyte histamine-releasing activity ( 0 ). The leukocytes exposed to the heated lysates, were then challenged with fresh lysate, and histamine release was determined (O). Mean total leukocyte histamine concentration 0.122 sg/ml. Exposure of leukocytes to heated lysate inhibited histamine release induced by three of the four agents tested (Table I ). Histamine release induced by goat antihuman IgE, compound 48/80, and fresh leukocyte lysate was inhibited by 51, 69, and 63%, respectively, in cells treated with heated lysate. The inhibition of histamine release was significant with a P value of < 0.001 for these three agents. Histamine release induced by staphylococcal antigen extract was not significantly affected by treatment of the leukocytes with heated lysate. Therefore, heated leukocyte lysates con- In a typical separation, the protein concentration was reduced by a factor of six after ultrafiltration, but the inhibitory activity of the ultrafiltrate was essentially the same as the unfractionated lysate. Therefore, ultrafiltration provided a useful initial step in the purification of the inhibitory activity, and the results suggested that the inhibitor was of low molecular weight.
Chromatographic separation on Sephadex G-25 was carried out to further characterize the inhibitory activity. The ultrafiltrates of 38°C heated lysates were applied to a Sephadex G-25 column, and fractions, diluted 1: 1,000, were assayed for inhibition of histamine release. A single peak of inhibitory activity was detected in each of five separations (Fig. 4) . The elution profile of the inhibitory activity again suggested a low molecular weight confirming the impression gained from the ultrafiltration data.
In view of the very low molecular weight of the inhibitor, subsequent separations were carried out on Sephadex G-15. To obtain relatively salt-free preparations, leukocyte lysates were prepared in distilled water rather than Tris A, and the chromatographic separa- FIGURE 5 Chromatographic separation of the heated lysate inhibitor on Sephadex G-15 equilibrated with distilled water. Fractions were diluted 1: 1,000 and assayed for inhibition of leukocyte histamine release. Control histamine release from leukocytes not exposed to inhibitor, 45.5%. Mean total leukocyte histamine 0.104 ,g/ml.
tions were carried out in water rather than buffer. These lysates were heated at 380C for 60 min, and ultrafiltrates were prepared as before. The ultrafiltrates were applied to the Sephadex G-15 column, and fractions, diluted 1: 1,000, were assayed for inhibition of histamine release. Column chromatography on Sephadex G-15 failed to provide additional separation, and a single peak of inhibitory activity was again obtained in each of 10 separations (Fig. 5) .
Assays Leukocytes were incubated for 60 min with varied concentrations of this partially purified inhibitor. The cells were then collected by centrifugation and reincubated with fresh lysate to determine the percent inhibition of histamine release. This partially purified material produced 80-90% inhibition of histamine release at concentrations of less than 10 ng/ml, and the 50% inhibitory concentration was approximately 0.25 ng/ml (Fig. 6) .
Generation of the inhibitor from the partially purified lymphocyte and granulocyte histamine-releasing factors. Since the lysates employed in these studies consisted of a mixture of lymphocytes and granulocytes, it was of interest to determine which type of cell contributed to the inhibitory activity. Lymphocyte and granulocyte suspensions of 95-100% purity were prepared, and they contained no erythrocytes and less than one platelet/two leukocytes. Lysates of these purified suspensions and of the standard mixed leukocyte suspensions were prepared, incubated at 38°C for 60 min, and assayed for inhibition of leukocyte histamine release. The heated lysates of lymphocyte, granulocyte, and mixed leukocyte suspensions, diluted 1:1,000, inhibited histamine release by 64, 80, and 90%, respectively. Our previous studies revealed that lymphocytes and granulocytes also contain histamine-releasing factors (2) . Therefore, studies were done to determine if the inhibitor of histamine release could be derived from the histamine-releasing factor. Lymphocyte and granulocyte lysates were subjected to gel filtration on Sephadex G-25, and the fractions were assayed for histaminereleasing activity. A single peak of activity was eluted between the 13,000 mol wt marker (cytochrome c) and the 1,300 mol wt marker (cyanocobalamin) (Fig. 7) . The lymphocyte and granulocyte histamine-releasing factors had nearly identical elution profiles (Fig. 8) .
Mixtures of the most active fractions from the lymphocyte and granulocyte separations were rechromatographed, and a single peak of activity was again obtained (Fig. 8) . Therefore, the human lymphocyte and granulocyte histamine-releasing factors appear to be the same, and they have an estimated molecular weight of approximately 5,000 daltons. These partially purified lymphocyte and granulocyte histamine-releasing factors were incubated at 380C for 60 min. The resulting preparations were then subjected to gel filtration on Sephadex G-25, and the fractions were assayed for inhibition of histamine release. A single peak of inhibitory activity was detected for each preparation, and the activity was eluted in the same position as that from the crude heated lysates (Fig. 9) . The results sugest that the inhibitor of histamine release may be generated from the partially purified histamine-releasing factor. DISCUSSION Regulation of the extracellular histamine levels in vivo may be vital to the production and control of the acute inflammatory response. Since histamine is normally sequestered in the *storage granules of tissue mast cells and circulating basophils, one aspect of its regulation concerns the liberation of histamine from these storage sites. Therefore, many important studies have appeared on the mechanisms of histamine release (2, (8) (9) (10) (11) 14) .
An Inhibitor of
The second aspect of the regulation of the histamine levels in inflammation concerns the mechanisms of limitation of the amounts of histamine in the extracellular spaces. This aspect of histamine regulation is probably of considerable importance in the control of inflammation, but definitive studies in this area have only recently begun to appear. Removal of extracellular histamine by enzymatic destruction or cellular uptake (3) would provide one type of regulation. However, a more efficient means of regulation would be to control histamine release.
Several mechanisms for the inhibition of histamine release have been investigated. The role of cyclic AMP as an inhibitor of histamine release has been fairly well established since agents which increase the intracellular levels of cyclic AMP inhibit a variety of histamine release systems (3, 14-16 ). In addition, substances which interfere with Ca"+ metabolism can inhibit the release process (4, 8, 17, 18) . However, most of these inhibitors are exogenous substances, and to our knowledge, no natural, cell-derived inhibitors of histamine release have been described previously.
In the present studies we describe such a natural inhibitor which is generated from ultrasonically disrupted leukocytes during incubation at 380C. Incubation of intact leukocytes with inhibitory lysates results in progressive impairment of the ability of the cells to release histamine when challenged with a variety of agents ( Fig. 3 and Table I ). Thus, heated leukocyte lysates inhibit histamine release induced by antihuman IgE, compound 48/80, or fresh leukocyte lysate (Table I) . Leukocyte lysate and antiIgE are known to release histamine from human leukocytes by an active process which resembles a secretory reaction (4, 5, 9) . Compound 48/80 has been best studied in the rat mast cell system, and a similar active process seems to be involved in histamine release in this system (10) . Although the mechanism of action of compound 48/80 on human cells is not well understood, it is tempting to speculate that the inhibitor in heated leukocyte lysates may inactivate binding sites common to these three agents or inhibit some component of the release mechanism common to all three types of histamine release. The failure of the heated lysate factor to inhibit histamine release induced by staphylococcal antigens may reflect a different mechanism of histamine release such as release during phagocytosis or pinocytosis of the bacterial extract (11) .
Although the exact mechanism of action of th2 h-ated lysate inhibitor is obscure, several of our studies provide information in this regard. The inhibition of histamine release from cells exposed to heated lysate at 1348 M. T. Kelly and A. White 4VC (Fig. 3) suggests that membrane-binding phenomena may be involved. (19, 20) . The result is apparent inhibition of histamine release. Desensitization is difficult to exclude in our system, but it does not seem to apply in the strict sense because the cells are exposed to the inhibitor under conditions which are optimal for histamine release. Nevertheless, a phenomenon similar to desensitization could be implicated in our system.
The inhibitor of histamine release in heated leukocyte lysates appears to be of low molecular weight since it readily passes through membrane ultrafilters which exclude molecules of greater than 1,000 mol wt. The inhibitory activity was eluted from Sephadex G-25 considerably later than cyanocobalamin which has an approximate mol wt of 1,300 daltons (Fig. 4) . It was also retarded by Sephadex G-15 (Fig. 5) . These findings suggest that the heated lysate inhibitor has a molecular weight of less than 1,000 daltons. Preliminary analysis on the mass spectrometer of the partially purified inhibitor eluted from Sephadex G-15 revealed a possible mol wt of 355 daltons.
Our studies suggest that the inhibitor of histamine release may be derived from the leukocyte histaminereleasing factor. The histamine-releasing factors from human lymphocytes and granulocytes were eluted as identical, single peaks from Sephadex G-25, and they had an estimated mol wt of 5,000 (Figs. 7 and 8 ). This is in contrast to our earlier studies which indicated that these factors sedimented at 100,000 g (2) . This discrepancy may be explained by binding of the low molecular weight histamine-releasing factors to larger molecules during centrifugation. Such binding has been demonstrated for a histamine-releasing factor derived from rabbit leukocytes (21) .
Incubation of these partially purified histamine-releasing factors at 380C produced inhibitors of hista- mine release which were nearly identical to those from the crude leukocyte lysates (Fig. 9) . These results suggest that the inhibitor of histamine release in heated leukocyte lysates may be a fragment of the leukocyte histamine-releasing factor which is generated during its inactivation at 380C. An Inhibitor of Histamine Release from Human Leukocytes tivity was rapidly destroyed by dilute acid, but was relatively stable in dilute alkali. Whatever the nature of this inhibitor, it is remarkably potent, producing up to 90% inhibition of histamine release at a concentration of only 10 ng/ml.
In view of the very small amounts of material required to produce inhibition, it is tempting to suggest a role for a second messenger, such as cyclic AMP, which might amplify the inhibitory effect (19, 22) . Histamine is one cyclic AMP-active agent which could play a role in this system, but the purified inhibitor did not contain detectable histamine. Cyclic AMP itself might also be considered, but much greater concentrations are usually required to exert an effect (3, (14) (15) (16) . In addition, preliminary experiments revealed that the cyclic AMP-active agent, theophylline, and the heated lysate inhibitor produced only additive inhibition of histamine release. Therefore, we have no evidence at present to implicate the cyclic AMP system in the inhibition of histamine release by heated leukocyte lysates.
The results presented suggest that human lymphocytes and granulocytes contain a heat-labile, low molecular weight histamine-releasing factor. An inhibitor of histamine release is generated during thermal inactivation of this histamine-releasing factor. This inhibitor appears to be of extremely low molecular weight, and it could be a fragment of the histamine-releasing factor which is released during heat-inactivation.
The possible implications for such an inhibitor of histamine release in vivo are evident. Leukocytes are early inhabitants of most inflammatory foci, and since the inhibitor is readily generated at 380 C, it could limit histamine release in vivo. Inhibition of histamine release by this human leukocyte factor could provide an efficient means for controlling that part of the inflammatory response mediated by histamine.
